AbbVie Inc. (ABBV)
AbbVie: The Market Is Getting It Wrong
AbbVie delivered a resilient Q4 with 10% YoY revenue growth and strong immunology performance, despite a post-earnings stock selloff. Their adjusted EPS grew 25% YoY, beating estimates, while operating margin expanded 360 bps, demonstrating improved efficiency. Forward guidance for FY2026 EPS of $14.37-$14.57 implies 13% growth, exceeding analyst expectations by $0.25 per share.
AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot
AbbVie has significantly outperformed prior immunology sales projections, with Skyrizi and Rinvoq now expected to reach $38 billion by 2030. ABBV's oncology and neuroscience pipelines have expanded via ImmunoGen and Cerevel acquisitions, supporting robust growth beyond immunology. Sales and EPS growth through 2030 are forecast to outpace most peers, with a projected 6.6% sales CAGR and 7.7% EPS CAGR.
AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise
AbbVie Inc. retains a Strong Buy rating, driven by a positive earnings surprise in Q4 2025, notably due to HUMIRA outperformance. Despite ongoing HUMIRA declines, ABBV demonstrates robust growth in its immunology and neuroscience portfolios, supporting continued optimism. The company's ability to exceed expectations amid headwinds underscores management's effective execution and portfolio diversification.
AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake
AbbVie Inc. has delivered strong long-term returns and maintains a >3% dividend yield, but recent Q4 earnings and guidance have tempered my near-term enthusiasm. ABBV's immunology and neuroscience divisions are thriving, with Skyrizi and Rinvoq driving robust growth, yet competition and market saturation present future risks. Management projects high single-digit revenue CAGR through the decade, but detailed 2026 guidance limits upside surprise and leaves little room for error.
AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)
AbbVie Inc. faces investor skepticism on growth durability beyond Immunology, despite strong SKYRIZI and RINVOQ performance offsetting HUMIRA's decline. ABBV's Q4 2025 saw 18% Immunology growth and 10% total revenue growth, but Oncology and Aesthetics portfolios declined, highlighting diversification challenges. 2026 adjusted EPS guidance of $14.37–$14.57 excludes unpredictable IPR&D and milestone costs, raising concerns about reliance on M&A for future growth.
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View
ABBV beats Q4 earnings and revenue estimates, but shares slip as Rinvoq and oncology sales miss expectations despite strong 2026 EPS guidance.
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AbbVie (ABBV) Tops Q4 Earnings and Revenue Estimates
AbbVie (ABBV) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.16 per share a year ago.
AbbVie Revenue Rises on Immunology Growth
AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn's disease drugs Skyrizi and Rinvoq.
Buy AbbVie Stock Before Q4 Earnings? Here's What to Know
ABBV heads into Q4 earnings with Skyrizi and Rinvoq driving growth, Humira sales sliding, and shares trading at a discount to the industry.
Wall Street Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
